Singapore markets closed

Medexus Pharmaceuticals Inc. (MEDXF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
2.1200+0.1488 (+7.55%)
At close: 03:18PM EST

Medexus Pharmaceuticals Inc.

35 Nixon Road
Unit 1
Bolton, ON L7E 1K1
Canada

https://www.medexus.com

Sector(s)Healthcare
IndustryDrug Manufacturers—Specialty & Generic
Full-time employees

Key executives

NameTitlePayExercisedYear born
Mr. Kenneth d'EntremontCEO & Director688.3kN/AN/A
Mr. Bill PoncySr. VP of Commercial Operations - United States439.69kN/AN/A
Mr. Michael David AdelmanGen. Mang., U.S. Operations576.85kN/A1971
Mr. Marcel KonradChief Financial OfficerN/AN/A1976
Ms. Tina Byers CFAExec. of Investor RelationsN/AN/AN/A
Mr. Ian C. Wildgoose BrownGen. Counsel & Corp. Sec.N/AN/AN/A
Mr. Brian PetersVP of Sales & Marketing - United StatesN/AN/AN/A
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Medexus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada and the United States. The company's primary products are Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis psoriasis, and juvenile idiopathic arthritis; IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with Hemophilia B; and Rupall, a prescription allergy medication. Its products portfolio also include Treosulfan, a conditioning agent used prior to stem cell transplantation; and Triamcinolone Hexacetonide for intra-articular, intrasynovial, or periarticular use in adults and adolescents for the symptomatic treatment of subacute and chronic inflammatory joint diseases. The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in Bolton, Canada.

Corporate governance

Medexus Pharmaceuticals Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.